Company intelligence / Profile preview

Tianyu Chang’an Group

Ownership: Private
Development stage: Commercial

Overview

Tianyu Chang’an Group is the only manufacturer of Lauromacrogol Injection in China, holding patent protection for both the raw material and finished injection. The product is included in China's healthcare insurance system and used by over 2,000 top-tier hospitals across multiple specialties including gastroenterology, anorectal surgery, general surgery, plastic surgery, and interventional radiology. The group has established strong relationships with government health departments and medical associations.

Therapeutic areas: OtherGastroenterologyCardiovascularDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Chinese Medical AssociationChinese Medical Doctors Association

Beyond the preview

Go deeper on Tianyu Chang’an Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianyu Chang’an Group.

Explore the full profile